Novo Nordisk Weighs Direct NYSE Listing as Pipeline Deals and Data Pile Up
Published on 09/26/2026 at 06:51 | Editorial boerse-global.de
Novo Nordisk is exploring a direct listing on the New York Stock Exchange, a move that would give the Danish drugmaker a more immediate foothold with US investors and potentially replace its current American Depositary Receipt structure. CEO Mike Doustdar told the Financial Times on Wednesday that the company is open to such a step, which would sit alongside its long-standing home listing in Copenhagen. Reuters also reported on the deliberations.
The US capital-markets review lands in the middle of a broader reassessment of Novo Nordisk's growth trajectory — and a flurry of pipeline and partnership news that management hopes will shift the conversation toward life after semaglutide.
CagriSema data sharpen the pipeline picture
Fresh Phase 3 results for the company's lead candidate, CagriSema, arrived on Monday. In the REIMAGINE 5 trial, the investigational drug produced an average weight loss of 12.4% after 60 weeks in adults with type 2 diabetes, against 9.1% for Eli Lilly's tirzepatide at a 5-milligram dose. The study also demonstrated non-inferior HbA1c reduction. In the separately assessed REDEFINE 9 trial, CagriSema delivered 21% weight loss at 68 weeks versus placebo. Novo Nordisk is banking heavily on the drug combination to broaden its cardiometabolic portfolio.
Two licensing deals in quick succession
Alongside its own science, the group has been buying in outside expertise. A worldwide licensing agreement with Swedish specialist Nanexa hands Novo Nordisk access to a delayed-release platform built on the company's PharmaShell technology. The pact can cover as many as five development programs across obesity, type 2 diabetes and cardiometabolic disease.
The aim is to stretch dosing intervals well beyond the current weekly standard: peptide medicines coated with the inorganic particle layer could eventually be given once a month or once a quarter. Under the financial terms, the deal carries a total value of up to EUR 1.165 billion, with EUR 615 million earmarked for upfront payments and the hitting of defined development and approval milestones. The remainder is tied to future sales thresholds, supplemented by low single-digit royalties on global net sales. Novo Nordisk will shoulder global clinical development and later commercialization on its own.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
That transaction follows a licensing and research partnership struck earlier this month with Orbis Medicines worth up to USD 1.4 billion, focused on novel oral therapies for cardiometabolic conditions. It also joins a string of recent tie-ups, including an agreement with Kallyope, as the company reaches for external know-how.
Why dosing intervals matter
In metabolic medicine, longer dosing windows are seen as a decisive lever for treatment adherence — and rivals are chasing the same idea, with Eli Lilly working through a partnership with Camurus. The pressure is set to build as patent protection for the blockbuster semaglutide expires in the early 2030s.
Henrik Hallengren Laustsen, an analyst at Jyske Bank, said the Nanexa partnership underscores the group's determination to open new growth fields, though he characterized it as a relatively small deal measured against the Danish company's size.
A 2030 blueprint, framed as ambition
Management's strategic goals through 2030 include launching more than five blockbuster medicines and expanding global patient reach beyond 60 million people. Executives have been explicit that these are strategic ambitions rather than financial forecasts.
Near-term catalysts are close at hand. Between September 28 and October 2, the company will present 44 scientific contributions at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, including new CagriSema data and material on a tablet form of Wegovy.
Shares stuck in neutral
The stock has been unmoved through a weak trading week. Novo Nordisk closed Friday at EUR 34.05, and was quoted at EUR 33.95 today, leaving it down 23% since the start of the year. Shares in Nanexa jumped on the Stockholm exchange after the deal was announced, while Novo Nordisk investors remain focused on clinical progress for the company's next-generation treatments.
Ad
Novo Nordisk Stock: New Analysis - 26 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
